Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology
Emile M. Youssef,
Brandon Fletcher,
Dannelle Palmer
и другие.
Frontiers in Medicine,
Год журнала:
2025,
Номер
11
Опубликована: Янв. 13, 2025
Gene
therapy
has
long
been
a
cornerstone
in
the
treatment
of
rare
diseases
and
genetic
disorders,
offering
targeted
solutions
to
conditions
once
considered
untreatable.
As
field
advances,
its
transformative
potential
is
now
expanding
into
oncology,
where
personalized
therapies
address
immune-related
complexities
cancer.
This
review
highlights
innovative
therapeutic
strategies,
including
gene
replacement,
silencing,
oncolytic
virotherapy,
CAR-T
cell
therapy,
CRISPR-Cas9
editing,
with
focus
on
their
application
both
hematologic
malignancies
solid
tumors.
CRISPR-Cas9,
revolutionary
tool
precision
medicine,
enables
precise
editing
cancer-driving
mutations,
enhancing
immune
responses
disrupting
tumor
growth
mechanisms.
Additionally,
emerging
approaches
target
ferroptosis—a
regulated,
iron-dependent
form
death—offering
new
possibilities
for
selectively
inducing
death
resistant
cancers.
Despite
significant
breakthroughs,
challenges
such
as
heterogeneity,
evasion,
immunosuppressive
microenvironment
(TME)
remain.
To
overcome
these
barriers,
novel
like
dual-targeting,
armored
cells,
combination
checkpoint
inhibitors
ferroptosis
inducers
are
being
explored.
rise
allogeneic
“off-the-shelf”
offers
scalable
more
accessible
options.
The
regulatory
landscape
evolving
accommodate
advancements,
frameworks
RMAT
(Regenerative
Medicine
Advanced
Therapy)
U.S.
ATMP
(Advanced
Therapy
Medicinal
Products)
Europe
fast-tracking
approval
therapies.
However,
ethical
considerations
surrounding
CRISPR-based
editing—such
off-target
effects,
germline
ensuring
equitable
access—remain
at
forefront,
requiring
ongoing
oversight.
Advances
non-viral
delivery
systems,
lipid
nanoparticles
(LNPs)
exosomes,
improving
safety
efficacy
By
integrating
innovations
addressing
concerns,
poised
revolutionize
cancer
treatment,
providing
durable,
effective,
Язык: Английский
Progress and challenges in developing allogeneic cell therapies
Cell stem cell,
Год журнала:
2025,
Номер
32(4), С. 513 - 528
Опубликована: Апрель 1, 2025
The
new
era
of
cell
therapeutics
has
started
with
autologous
products
to
avoid
immune
rejection.
However,
derived
from
allogeneic
cells
could
be
scaled
and
made
available
for
a
much
larger
patient
population
if
rejection
reliably
overcome.
In
this
review,
we
outline
gene
engineering
concepts
aimed
at
generating
immune-evasive
cells.
First,
summarize
the
current
state
therapies,
second,
compile
still
limited
data
replacement
therapies.
We
emphasize
advances
in
fast-developing
field
provide
an
optimistic
outlook
future
Язык: Английский
Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Авг. 30, 2024
Induced
pluripotent
stem
cells
(iPSCs)
have
emerged
as
a
revolutionary
tool
in
cell
therapies
due
to
their
ability
differentiate
into
various
types,
unlimited
supply,
and
potential
off-the-shelf
products.
New
advances
iPSC-derived
immune
generated
potent
iNK
iT
which
showed
robust
killing
of
cancer
animal
models
clinical
trials.
With
the
advent
advanced
genome
editing
technologies
that
enable
development
highly
engineered
cells,
here
we
outline
12
strategies
engineer
iPSCs
overcome
limitations
challenges
current
cell-based
immunotherapies,
including
safety
switches,
stealth
edits,
avoiding
graft-versus-host
disease
(GvHD),
targeting,
reduced
lymphodepletion,
efficient
differentiation,
increased
Язык: Английский
Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies
Blood Reviews,
Год журнала:
2024,
Номер
unknown, С. 101241 - 101241
Опубликована: Сен. 1, 2024
Язык: Английский
CAR-T cell therapy in developing countries: how long should we wait?
Journal for ImmunoTherapy of Cancer,
Год журнала:
2024,
Номер
12(12), С. e009611 - e009611
Опубликована: Дек. 1, 2024
Low-
and
middle-income
countries
(LMICs)
face
a
significant
burden
of
cancer
prevalence
incidence.
However,
the
survival
rates
for
patients
with
in
these
regions
are
notably
lower
than
those
high-income
countries,
primarily
due
to
late
diagnosis
limited
access
advanced
treatments.
Chimeric
antigen
receptor
(CAR)
T-cell
therapy
has
demonstrated
promising
outcomes
certain
terminally
ill
cancer,
yet
this
treatment
remains
LMICs,
including
Nepal.
The
Center
Regenerative
Medicine
Nepal
initiated
efforts
make
CAR-T
cell
accessible
at
substantially
reduced
cost.
This
initiative
includes
successful
research
test
feasibility
local
laboratory
capabilities
using
reagents
sourced
locally
or
from
developed
countries.
Additionally,
Good
Manufacturing
Practicies
(GMP)
grade
manufacturing
facility
is
being
established
commence
clinical
manufacturing.
endeavor
encountered
several
challenges,
technical
difficulties,
regulatory
barriers,
resource
limitations,
which
could
provide
valuable
insights
other
developing
experience
highlights
importance
interdisciplinary
collaboration,
shared
knowledge,
funding,
innovative
solutions
global
scientific
community
achieve
equitable
medical
Язык: Английский